This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Shire Pharmaceuticals Group PLC

Drug Names(s): HCV-796

Description: HCV-796 is a novel polymerase inhibitor. It has the potential to interfere with the replication of hepatitis C virus.

Deal Structure: ViroPharma and Wyeth
In December 1999, ViroPharma entered into an alliance with Wyeth, through its Wyeth Pharmaceuticals division, to discover, develop and commercialize additional novel inhibitors of Hepatitis C virus (HCV). Together with Wyeth, ViroPharma has discovered multiple, chemically distinct compound series that target the RNA replication process (RNA Polymerase) of HCV.

In April 2008, ViroPharma announced that ViroPharma and Wyeth do not expect to continue to collaborate on future development of hepatitis C treatment candidates.

Wyeth and Pfizer
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The acquisition was completed in October 2009.

ViroPharma and Shire
In November 2013, Shire and ViroPharma entered into a merger...See full deal structure in Biomedtracker

Partners: Pfizer Inc.

HCV-796 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug